In a cross-sectional study comparing leptin serum levels between people with MS and a control group, a significant increase in leptin levels was described in individuals with MS, accompanied by a decrease in orexin-A and TGF-β (Moharami et al., 2022). This evidence concerns the gene LEP and myeloid sarcoma.